Home

Investor Relations

TSX:LEAF: 11.00
0.30
2.8% Volume: 118,370 Pricing delayed 20 minutes October 20, 2017

Company Overview

MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

Latest News

17 Oct 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, welcomes and supports the clarity provided by the Staff Notice issued by the Toronto Stock Exchange ("TSX") on October 16, 2017 which the Company believes levels the playing field for listed cannabis issuers in Canada . Since its listing, MedReleaf has been and continues to operate with the goal of being at all times fully compliant with the TSX requirements pursuant to Sections 306, Section 325, and Part VII (collectively the "Requirements") in the TSX Company Manual and is confident that the review and enforcement of the Staff Notice will have no impact on its operations or listing on the TSX. "The TSX Staff Notice removes the uncertainty for issuers that were already adhering to the Requirements and validates our strategy of focusing on markets that are federally legal and offer federal regulatory guidelines," said Neil Closner , CEO of ...
4 Oct 2017.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced the launch of a topical cream, the first Canadian Licensed Producer to do so. The cream is specifically formulated to provide superior absorption with MedReleaf's award-winning high CBD strain and was developed in response to patient feedback for topical applications of CBD. MedReleaf Topical Cream mixes and integrates with the cannabis oil to create an easy-to-use topical agent for direct application to affected areas. "Our product development team has devised a method to provide Canadian patients with a much sought-after, high-absorption, topical cream that is within the strict limitations afforded by the current regulations," said Neil Closner , CEO of MedReleaf . "This is further evidence of MedReleaf's continued leadership in setting the standard for product innovation and focus on the patient experience." "The Dermatology ...
25 Sep 2017.
MedReleaf Corp. (TSX: LEAF) (" MedReleaf " or the " Company ") announced the results of the vote on the election of directors at the annual meeting of shareholders held today. On a vote by ballot, each of the five nominees proposed by management was elected as a director of the Company to hold office until the close of the next annual meeting of shareholders or until the director's successor is elected or appointed. Nominee Votes For % For Votes Withheld % Withheld Norma Beauchamp 55,205,572 99.92% 43,127 0.08%




Neil Closner 55,204,807 99.92% 43,892 0.08% Ronald Funk 55,204,047 99.92% 44,652 0.08%




Deborah Rosati 55,203,372 99.92% 45,327 0.08% Lloyd M. Segal 55,205,147 99.92% 43,552 0.08% About MedReleaf Corp. MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICHGMP and ISO 9001 certified cannabis producer in North America , MedReleaf is a R&D-driven company ...